United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised options for 10,000 shares of common stock at an exercise price of $135.42 per share and then sold 10,000 shares in open-market trades at prices ranging from about $569.28 to $580.03. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After the sales, he directly holds 18,876 shares of United Therapeutics common stock.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on April 10, 2026. The options were originally granted with an expiration date of March 15, 2027.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices ranging from about $567 to $573 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 shares directly and also reported indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a pre-planned transaction. On April 9, 2026, he exercised options for 10,000 shares of Common Stock at an exercise price of $135.42 per share.
On the same date, he sold a total of 10,000 shares of Common Stock in multiple open-market trades at prices reported between about $574.18 and $582.30. These transactions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating they were pre-scheduled.
Following the transactions, Edgemond directly owned 18,876 shares of UNITED THERAPEUTICS Common Stock, maintaining a meaningful equity stake while monetizing the shares received from the option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in open-market transactions. The sales occurred at prices around the mid-$570s to low-$580s per share, with reported weighted average prices including $575.04 and $580.84.
The exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following these transactions, Rothblatt directly holds 40,513 shares of common stock and 74,000 stock options, with additional indirect holdings through a spouse and multiple family trusts.
United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 8, 2026, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in multiple open-market trades at prices generally ranging from about $565 to $586 per share, leaving 40,513 shares held directly. Additional common shares are held indirectly through her spouse and various family trusts as described in the filing. All option exercises and related sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. She exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market trades, with reported prices including $556.89, $562.35 and $569.62 per share. Following these transactions, she held 40,513 shares of common stock directly, plus additional indirect holdings through her spouse and family trusts, including positions of 324,518 and 258,117 shares as of the filing.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share. On the same date, he sold 10,000 shares of common stock in multiple open-market trades at prices generally in the mid-$550s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of common stock and 112,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold the resulting shares in a planned transaction. On 2026-04-06, she exercised options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold 9,500 shares in multiple open-market trades at prices ranging from $552.37 to $566.04.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following these trades, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired 9,500 shares on April 2, 2026. She then sold 9,500 shares of common stock the same day in a series of open‑market transactions at prices in the mid‑$500s per share, leaving her with 40,513 shares held directly. The filing also shows substantial additional indirect holdings through family trusts and a spouse. The exercise and sale were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of up to 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in multiple open‑market transactions. The sales occurred at weighted average prices within ranges described in the filing, including from $551.68 to $571.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, Edgemond directly holds 18,876 shares of United Therapeutics Common Stock.